Philip Oettinger is a partner in the life sciences practice at Wilson Sonsini Goodrich & Rosati, where he focuses primarily on medical device, biotechnology, pharmaceutical, diagnostic, and digital health companies. His practice involves assisting private and public companies with corporate governance, initial public offerings, mergers and acquisitions, public company reporting, and private equity and debt financings. He routinely works with incubators on structuring matters and balancing their rights with those of the companies they are forming. Philip serves as co-chair of the Finance Committee and a member of the Compensation Committee.

From 1995 until 2000, Philip was with the Securities and Exchange Commission in Washington, D.C., where he inspected stock exchanges, worked on corporate finance matters, led enforcement investigations, and served as special counsel to Commissioner Laura S. Unger.

  • Acclarent
  • Ardian
  • Avinger
  • Cutera
  • Elysium Therapeutics
  • Exploramed
  • Forsight Vision 4
  • ForteBio
  • Foundry
  • FoxHollow Technologies
  • Globavir Biosciences
  • iRhythm Technologies
  • Synecor
  • Theron Pharmaceuticals
  • Represented Ardian in its merger with Medtronic
  • Represented ForteBio in its merger with Pall Corporation
  • Representation of incubators Exploramed, Foundry, Forsight Labs, and Inceptus Medical
  • Represented Avinger, Cutera, FoxHollow Technologies, and Kyphon in their initial public offerings
  • Represented Emergent Medical Partners, InterWest, Morgenthaler, Three Arch, and Vertical Group in various venture capital financings
  • Represented FoxHollow Technologies in its acquisition of Kerberos Proximal Solutions and in transactions with Merck
  • Represented SurgRx and Acclarent in their mergers with Johnson & Johnson
  • J.D., American University, Washington College of Law, 1994
    With High Honors
  • B.S., Cornell University, 1991
  • Bar of the District of Columbia
  • State Bar of California
  • State Bar of Massachusetts
  • State Bar of New York